Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Weighted Average) (2022 - 2025)

Axsome Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $49.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.83% year-over-year to $49.7 million; the TTM value through Dec 2025 reached $49.7 million, up 3.83%, while the annual FY2025 figure was $49.7 million, 3.83% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $49.7 million at Axsome Therapeutics, up from $49.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $49.7 million in Q4 2025 and bottomed at $38.3 million in Q1 2022.
  • The 4-year median for Shares Outstanding (Weighted Average) is $46.4 million (2023), against an average of $45.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 13.57% in 2023 before it rose 3.12% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $40.7 million in 2022, then grew by 11.73% to $45.4 million in 2023, then rose by 5.48% to $47.9 million in 2024, then increased by 3.83% to $49.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Shares Outstanding (Weighted Average) are $49.7 million (Q4 2025), $49.4 million (Q3 2025), and $49.4 million (Q2 2025).